Dopamine D4 Receptor, but Not the ADHD-Associated D4.7 Variant, Forms Functional Heteromers with the Dopamine D2S Receptor in Th

Total Page:16

File Type:pdf, Size:1020Kb

Dopamine D4 Receptor, but Not the ADHD-Associated D4.7 Variant, Forms Functional Heteromers with the Dopamine D2S Receptor in Th Molecular Psychiatry (2012) 17, 650–662 & 2012 Macmillan Publishers Limited All rights reserved 1359-4184/12 www.nature.com/mp ORIGINAL ARTICLE Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain S Gonza´lez1, C Rangel-Barajas2, M Peper3, R Lorenzo3, E Moreno1, F Ciruela4, J Borycz5, J Ortiz6, C Lluı´s1, R Franco7, PJ McCormick1, ND Volkow8, M Rubinstein3, B Floran2 and S Ferre´ 5 1Department of Biochemistry and Molecular Biology, Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas, University of Barcelona, Barcelona, Spain; 2Departamento de Fisiologı´a, Biofı´sica y Neurociencias, Centro de Investigacio´n y de Estudios Avanzados del Instituto Polite´cnico Nacional, Me´xico D.F., Me´xico; 3Departamento de Fisiologı´a y Biologı´a Molecular y Celular, Instituto de Investigaciones en Ingenierı´a Gene´tica y Biologı´a Molecular, Consejo Nacional de Investigaciones Cientı´ficas y Te´cnicas, Buenos Aires, Argentina; 4Unitat de Farmacologia, Departament Patologia i Terape`utica Experimental, Universitat de Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain; 5CNS Receptor-Receptor Interactions Unit, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA; 6Department of Biochemistry and Molecular Biology, Neuroscience Institute, Universitat Auto´noma de Barcelona, Bellaterra, Spain; 7Departamento de Neurociencias, Centro de Investigacio´nMe´dica Aplicada, Universidad de Navarra, Pamplona, Spain and 8National Institute on Drug Abuse, National Institutes of Health, Bethesda MD, USA Polymorphic variants of the dopamine D4 receptor have been consistently associated with attention-deficit hyperactivity disorder (ADHD). However, the functional significance of the risk polymorphism (variable number of tandem repeats in exon 3) is still unclear. Here, we show that whereas the most frequent 4-repeat (D4.4) and the 2-repeat (D4.2) variants form functional heteromers with the short isoform of the dopamine D2 receptor (D2S), the 7-repeat risk allele (D4.7) does not. D2 receptor activation in the D2S–D4 receptor heteromer potentiates D4 receptor- mediated MAPK signaling in transfected cells and in the striatum, which did not occur in cells expressing D4.7 or in the striatum of knockin mutant mice carrying the 7 repeats of the human D4.7 in the third intracellular loop of the D4 receptor. In the striatum, D4 receptors are localized in corticostriatal glutamatergic terminals, where they selectively modulate glutamatergic neurotransmission by interacting with D2S receptors. This interaction shows the same qualitative characteristics than the D2S–D4 receptor heteromer-mediated mitogen-activated protein kinase (MAPK) signaling and D2S receptor activation potentiates D4 receptor-mediated inhibition of striatal glutamate release. It is therefore postulated that dysfunctional D2S–D4.7 heteromers may impair presynaptic dopaminergic control of corticostriatal glutamatergic neurotransmission and explain functional deficits associated with ADHD. Molecular Psychiatry (2012) 17, 650–662; doi:10.1038/mp.2011.93; published online 16 August 2011 Keywords: dopamine receptors; receptor heteromers; ADHD; striatum; glutamate Introduction human D4 receptor contains a large number of polymorphisms in its coding sequence.4 The most Dopamine D4 receptors are expressed in the prefrontal extensive polymorphism is found in exon 3, a region cortex, in GABAergic interneurons and in gluta- that codes for the third intracellular loop (3IL) of the matergic pyramidal neurons, including their striatal receptor. This polymorphism consists of a variable 1–3 projections. D4 receptors have been implicated in number of tandem repeats in which a 48-bp sequence attention-deficit hyperactivity disorder (ADHD).1,4–6 exists as 2- to 11-fold repeats.7 The three most In fact, the prefrontal cortex and associated fronto- common variants contain 2, 4 and 7 repeats (D4.2, striatal circuits are critical for executive function and D4.4 and D4.7, respectively). D4.4 constitutes the most are involved in ADHD.5 The gene encoding the frequent variant, with a global frequency of 64%, 8 followed by D4.7 (21%) and D4.2 (8%). Importantly, a high prevalence of the D4.7 variant has been demon- Correspondence: Dr S Ferre´, National Institute on Drug Abuse, strated in children diagnosed with ADHD.5 Though Intramural Research Program, National Institutes of Health, 251 stimulation of the D4,7 variant has been reported to be Bayview Boulevard, Baltimore, MD 21224, USA. 9 E-mail: [email protected] less potent at inhibiting cAMP than D4.2 or D4.4, the Received 25 March 2011; revised 27 June 2011; accepted 7 July functional significance of these variants are poorly 2011; published online 16 August 2011 understood. Dopamine D2–D4 heteromers S Gonza´lez et al 651 Receptor heteromers are becoming the focus of fragment of 1500 bp. Equimolar quantities of both extensive research in the field of G-protein-coupled fragments were used to produce a third product 10 receptors. A receptor heteromer is currently defined corresponding to the myc-D4.2, myc-D4.4 or myc-D4.7- as a macromolecular complex composed of at least tagged gene using the sense primer (50-GTGCTCGAG two (functional) receptor units with biochemical CACCATGGGTAACCGAAGCACAG-30) and antisense properties that are demonstrably different from those primer without its stop codon (50-GCGAATTCTCAG of its individual components.10 In some cases, CAGCAAGCACGTAGAGCCTTACG-30), harboring un- receptor heteromers provide a framework in which ique XhoI and EcoRI restriction sites, respectively. to understand the role of receptors with no clear The fragments were then subcloned in-frame into functional significance, and example being the D3 XhoI/EcoRI sites of the pcDNA3.1 vector (Invitrogen, receptor, which forms heteromers with the D1 recep- Paisley, Scotland, UK). Next, the human cDNAs 11 tor and modifies its function. A recent study for the adenosine A1 receptor and dopamine D4.2, showed that in mammalian transfected cells, the long D4.4,D4.7 and D2S receptors, cloned in pcDNA3.1 isoform of the D2 receptor (D2L) heteromerizes with were amplified without their stop codons using sense the three main D4 receptor variants, D4.2,D4.4 and and antisense primers harboring unique XhoI and 12 D4.7. Interestingly, results from the same study EcoRI sites to clone A1,D4.2,D4.4 and D4.7 receptors in suggested that D4.7 was less effective in forming the RLuc and the yellow fluorescent protein (YFP) 12 heteromers with D2L receptors. In view of the corresponding vectors, and HindIII and BamHI to reported evidence of predominant co-localization of clone D2S in the RLuc and the YFP corresponding D4 receptors with the short isoform of the D2 receptor vectors. The mouse cDNAs for the D4 and D2S 2,3,13 (D2S) in corticostriatal glutamatergic terminals, we receptors, cloned in pCMV-SPORT6 (American Type first investigated if any of the three main human Culture Collection, Manassas, USA) and pReceiver- variants of the D4 receptor could interact both M16 vectors, respectively (GeneCopoeia, Rockville, physically and functionally with D2S. By using the MD, USA), were amplified without their stop codons Bioluminescence Resonance Energy Transfer (BRET) using sense and antisense primers harboring unique technique, here we show evidence for the formation XhoI and EcoRV sites to clone D4 receptor in the RLuc of heteromers between D2S and D4.2 and D4.4 variants corresponding vector, and XhoI and KpnI to clone D2S of the D4 receptor. In contrast, the D4.7 variant failed to receptor in the RLuc and the YFP corresponding form heteromers with the D2S receptor. In transfected vectors. The amplified fragments were subcloned to cells, we found a biochemical property of the D2S–D4 be in-frame into restriction sites of the multiple receptor heteromer, which consists of the ability of cloning sites of EYFP-N3 vector (enhanced yellow D2S receptor activation to potentiate D4 receptor- variant of YFP; Clontech, Heidelberg, Germany) or the mediated mitogen-activated protein kinase (MAPK) mammalian humanized pRluc-N1 vectors (Perkin- signaling. A similar result was observed in striata Elmer, Waltham, MA, USA) to give the plasmids that from wild-type (WT) mice, a species that expresses D4 express the receptors fused to either Rluc or YFP on receptors with a short 3IL comparable to human D4.2. the C-terminal end of the receptor (D4.2-RLuc, D4.4- In contrast, potentiation of D4 receptor-mediated RLuc, D4.7-Rluc, D2S-RLuc and A1-RLuc or D2S-YFP, MAPK signaling was not observed in transfected D4.7-YFP and D1-YFP, respectively). All constructs cells expressing D4.7 or in striata taken from knockin were verified by nucleotide sequencing and the mice carrying a humanized 7-repeat intracellular fusion proteins are functional and expressed at the loop identical to that found in human D4.7. Finally, membrane level (see Results). analyzing neurotransmitter release in striatal slices and with in vivo microdialysis in rats, evidence Cell culture and transient transfection was obtained for a key role of D2–D4 receptor inter- HEK (human embryonic kidney)-293T cells were action in the modulation of striatal glutamatergic grown in DMEM (Dulbecco’s modified Eagle’s neurotransmission. medium) (Gibco Paisley, Scotland, UK) supplemented with 2 mML-glutamine, 100 U mlÀ1 penicillin/strepto- mycin and 5% (v/v) heat-inactivated fetal bovine Materials and methods serum (all supplements were from Invitrogen). Fusion proteins and expression vectors CHO cell lines were maintained in a´-MEM The synthetic cDNAs for the human D4.2,D4.4 and, D4.7 medium without nucleosides, containing 10% fetal receptor gene (kindly provided by TP Sakmar, Rocke- calf serum, 50 mgmlÀ1 penicillin, 50 mgmlÀ1 strepto- feller University, USA) were amplified using sense mycin and 2 mML-glutamine (300 mgmlÀ1). Cells oligonucleotide primer (50-TCAACGGGACTTTCCA were maintained at 371C in an atmosphere of 5% 0 0 AAATGT-3 ) and antisense primer (5 -CTCCGAGAT CO2, and were passaged when they were 80–90% CAACTTCTGCTCGCTTCGGTTACCC-30), resulting in confluent, twice a week.
Recommended publications
  • D2 Receptors in the Paraventricular Nucleus Regulate Genital Responses and Copulation in Male Rats
    Pharmacology Biochemistry & Behavior, Vol. 39, pp. 177-181. ~ Pergamon Press plc, 1991. Printed in the U.S.A. 00914057/91 $3.00 + .00 D2 Receptors in the Paraventricular Nucleus Regulate Genital Responses and Copulation in Male Rats ROBERT C. EATON, VINCENT P, MARKOWSKI, LUCILLE A. LUMLEY, JAMES T. THOMPSON, JASON MOSES AND ELAINE M. HULL 1 Department of Psychology, State University of New York at Buffalo, Amherst, NY 14260 Received 30 April 1990 EATON, R. C., V. P. MARKOWSKI, L. A. LUMLEY, J. T. THOMPSON, J. MOSES AND E. M. HULL. D2 receptors in the paraventricular nucleus regulate genital responses and copulation in male rats. PHARMACOL BIOCHEM BEHAV 39(1) 177- 181, 1991.--The D2 dopamine receptor agonist quinelorane (LY-163502), microinjected into the paraventricular nucleus (PVN), affected genital responses of restrained supine male rats in a biphasic dose-dependent fashion. A moderate dose (1 Ixg) facilitated penile responses (intense erections and penile movements), and decreased the latency to the first response. A high dose of quinelorane (10 Ixg) facilitated seminal emission while inhibiting penile responses. The addition of the D1 antagonist SCH-23390 to the 1 ixg dose of quinelorane potentiated quinelorane's increase in seminal emission. We suggest that D1 receptors in the PVN may be antagonistic to D2 receptor-mediated seminal emission, and possibly also penile responses. In copulation tests 1 ~g quinelorane decreased mount latency, whereas 10 ixg quinelorane increased mount and intromission latencies and slowed copula- tory rate. Both 1 and 10 Ixg quinelorane, and also 1 and 10 Ixg of the mixed D1 and D2 agonist apomorphine, decreased the number of intromissions preceding ejaculation.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • Certificate of Analysis
    Print Date: Jan 15th 2016 Certificate of Analysis www.tocris.com Product Name: Quinelorane hydrochloride Catalog No.: 1519 Batch No.: 1 CAS Number: 97548-97-5 IUPAC Name: (5aR,9aR)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine dihydrochloride 1. PHYSICAL AND CHEMICAL PROPERTIES Batch Molecular Formula: C14H22N4.2HCl.2H2O Batch Molecular Weight: 355.3 Physical Appearance: Off-white crystalline solid Solubility: water to 25 mM Storage: Desiccate at RT Batch Molecular Structure: 2. ANALYTICAL DATA Melting Point: At 290°C HPLC: Shows >99.8% purity 1H NMR: Consistent with structure Mass Spectrum: Consistent with structure Microanalysis: Carbon Hydrogen Nitrogen Theoretical 47.33 7.94 15.77 Found 47.23 7.76 15.79 Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use bio-techne.com North America China Europe Middle East Africa Rest of World [email protected] Tel: (800) 343 7475 [email protected] Tel: +44 (0)1235 529449 www.tocris.com/distributors [email protected] Tel: +86 (21) 52380373 Tel:+1 612 379 2956 Print Date: Jan 15th 2016 Product Information www.tocris.com Product Name: Quinelorane hydrochloride Catalog No.: 1519 Batch No.: 1 CAS Number: 97548-97-5 IUPAC Name: (5aR,9aR)-5,5a,6,7,8,9,9a,10-Octahydro-6-propylpyrido[2,3-g]quinazolin-2-amine dihydrochloride Description: Storage: Desiccate at RT Dopamine D and D receptor agonist; K values are 5.7 and 3.4 23 i Solubility & Usage Info: nM respectively. water to 25 mM Physical and Chemical Properties: Stability and Solubility Advice: Batch Molecular Formula: C14 H 22 N 4 .2HCl.2H2 O Some solutions can be difficult to obtain and can be encouraged Batch Molecular Weight: 355.3 by rapid stirring, sonication or gentle warming (in a 45-60°C Physical Appearance: Off-white crystalline solid water bath).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow Et Al
    US 20070208029A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0208029 A1 Barlow et al. (43) Pub. Date: Sep. 6, 2007 (54) MODULATION OF NEUROGENESIS BY PDE Related U.S. Application Data INHIBITION (60) Provisional application No. 60/729,366, filed on Oct. (75) Inventors: Carrolee Barlow, Del Mar, CA (US); 21, 2005. Provisional application No. 60/784,605, Todd A. Carter, San Diego, CA (US); filed on Mar. 21, 2006. Provisional application No. Kym I. Lorrain, San Diego, CA (US); 60/807,594, filed on Jul. 17, 2006. Jammieson C. Pires, San Diego, CA (US); Kai Treuner, San Diego, CA Publication Classification (US) (51) Int. Cl. A6II 3 L/506 (2006.01) Correspondence Address: A6II 3 L/40 (2006.01) TOWNSEND AND TOWNSEND AND CREW, A6II 3/4I (2006.01) LLP (52) U.S. Cl. .............. 514/252.15: 514/252.16; 514/381: TWO EMBARCADERO CENTER 514/649; 514/423: 514/424 EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) The instant disclosure describes methods for treating dis eases and conditions of the central and peripheral nervous (73) Assignee: BrainCells, Inc., San Diego, CA (US) system by stimulating or increasing neurogenesis. The dis closure includes compositions and methods based on use of (21) Appl. No.: 11/551,667 a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the forma (22) Filed: Oct. 20, 2006 tion of new nerve cells. Patent Application Publication Sep. 6, 2007 Sheet 1 of 6 US 2007/0208029 A1 Figure 1: Human Neurogenesis Assay: budilast + Captopril Neuronal Differentiation budilast + Captopril ' ' ' 'Captopril " " " 'budilast 10 Captopril Concentration 10-8.5 10-8.0 10-7.5 10-7.0 10-6.5 10-6.0 10-5.5 10-5.0 10-4.5 10-40 ammammam 10-9.0 10-8.5 10-8-0 10-75 10-7.0 10-6.5 10-6.0 10-5.5 10-50 10-4.5 Conc (M) Ibudilast Concentration Patent Application Publication Sep.
    [Show full text]
  • Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats
    Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2017 Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats Keli A. Herr Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Psychology Commons Recommended Citation Herr, Keli A., "Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats" (2017). Dissertations. 3170. https://scholarworks.wmich.edu/dissertations/3170 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS by Keli A Herr A dissertation submitted to the Graduate College in partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University August 2017 Doctoral Committee: Lisa Baker, Ph.D., Chair Cynthia Pietras, Ph.D. Heather McGee, Ph.D. Missy Peet, Ph.D. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS Keli A. Herr, Ph.D. Western Michigan University After decades of opposition, a resurgence of interest in the psychotherapeutic potential of LSD is gaining acceptance in the medical community. Future acceptance of LSD as a psychotherapeutic adjuvant may be predicated on knowledge about its neural mechanisms of action. Preclinical drug discrimination assay offers an invaluable model to determine the neural mechanisms underlying LSD’s interoceptive stimulus effects.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0220580 A1 Rubin Et Al
    US 2016O220580A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0220580 A1 Rubin et al. (43) Pub. Date: Aug. 4, 2016 (54) SMALL MOLECULESCREENING FOR (60) Provisional application No. 61/497,708, filed on Jun. MOUSE SATELLITE CELL PROLIFERATION 16, 2011. (71) Applicant: PRESIDENT AND FELLOWS OF Publication Classification HARVARD COLLEGE, Cambridge, (51) Int. Cl. MA (US) A 6LX3/553 (2006.01) (72) Inventors: Lee L. Rubin, Wellesley, MA (US); A613 L/496 (2006.01) Amanda Gee, Alexandria, VA (US); A613 L/4439 (2006.01) Amy J. Wagers, Cambridge, MA (US) A613 L/404 (2006.01) (52) U.S. Cl. CPC ............. A6 IK3I/553 (2013.01); A61 K3I/404 (21) Appl. No.: 15/012,656 (2013.01); A61 K3I/496 (2013.01); A61 K 31/4439 (2013.01) (22) Filed: Feb. 1, 2016 (57) ABSTRACT The invention provides methods for inducing, enhancing or Related U.S. Application Data increasing satellite cell proliferation, and an assay for screen (63) Continuation-in-part of application No. 14/126,716, ing for a candidate compound for inducing, enhancing or filed on Jun. 13, 2014, now Pat. No. 9.248,185, filed as increasing satellite cell proliferation. Also provided are meth application No. PCT/US2012/042964 on Jun. 18, ods for repairing or regenerating a damaged muscle tissue of 2012. a Subject. Patent Application Publication Aug. 4, 2016 Sheet 1 of 44 US 2016/0220580 A1 FIG. A Patent Application Publication Aug. 4, 2016 Sheet 2 of 44 US 2016/0220580 A1 FIG. C. FIG. 2A Patent Application Publication Aug.
    [Show full text]
  • D1, Not D2, Dopamine Receptor Activation Dramatically Improves MPTP
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.20.305375; this version posted September 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. TITLE PAGE For repository in: bioRXiv D1, not D2, dopamine receptor activation dramatically improves MPTP- induced parkinsonism unresponsive to levodopa Richard B. Mailman, Ph.D. [email protected] Yang Yang. Ph.D. [email protected] Xuemei Huang, M.D., Ph.D. [email protected] Departments of Pharmacology and Neurology Penn State University College of Medicine Hershey PA 17033 Corresponding Author: Professor Richard B. Mailman Penn State University College of Medicine 500 University Dr., R130 Hershey PA 17033-0850 Phone: (717)531-3666 Email: [email protected] ` bioRxiv preprint doi: https://doi.org/10.1101/2020.09.20.305375; this version posted September 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. ABSTRACT Levodopa is the Parkinson’s disease standard-of-care, but continued loss of dopamine neurons with disease progression decreases its bioconversion to dopamine, leading to increased side effects and decreased efficacy. In theory, dopamine agonists could equal levodopa, but no approved oral “dopamine agonist” matches the efficacy of levodopa. Although there are consistent data in both primate models and in Parkinson’s disease showing that selective high intrinsic activity D1 agonists can equal levodopa, there are no data on whether such compounds would be effective in severe disease when levodopa efficacy is lower or even absent.
    [Show full text]
  • Sfn2015 Items of Interest
    Presentations and Posters of Interest Society for Neuroscience Meeting (2015) 34.01/A100. Estradiol rapidly attenuates ORL-1 receptor-mediated inhibition of proopiomelanocortin neurons via Gq-coupled, membrane-initiated signaling *K. M. CONDE1, C. MEZA2, M. KELLY3, K. SINCHAK4, E. WAGNER2; 1Grad. Col. of Biomed. Sci., 2Col. of Osteo. Med. of the Pacific, Western Univ. of Hlth. Sci., Pomona, CA; 3 Dept. of Physiol. & Pharmacol., Oregon Hlth. and Sci. Univ., Portland, OR; 4California State University, Long Beach, Long Beach, CA Ovarian estrogens act through multiple receptor signaling mechanisms that converge on hypothalamic arcuate nucleus (ARH) proopiomelanocortin (POMC) neurons. A subpopulation of these neurons project to the medial preoptic nucleus (MPN) to regulate lordosis. Orphanin FQ/nociception (OFQ/N) via its opioid-like receptor (ORL-1) regulates lordosis through direct actions on these MPN-projecting POMC neurons. Based o an ever-burgeoning precedence for fast steroid actions, we explored whether estradiol excites ARH POMC neurons by rapidly attenuating inhibitory ORL-1 signaling in these cells. Experiments were carried out in hypothalamic slices prepared from ovariectomized female rats injected one-week prior with the retrograde tracer Fluorogold into the MPN. During electrophysiologic recordings, cells were held at or near -60 mV. Post-hoc identification of neuronal phenotype was determined via immunohistofluorescence. In vehicle-treated slices OFQ/N caused a robust outward current/hyperpolarization via activation of GIRK channels. This OFQ/N-induced outward current was attenuated by 17-β estradiol (E2, 100nM). The 17α enantiomer of E2 had n effect. The OFQ/N-induced response was also attenuated by an equimolar concentration of E2 conjugated to BSA.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats
    Behavioral Pharmacology of Dopamine D2 and D3 Receptor Agonists and Antagonists in Rats. by Gregory T. Collins A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacology) in The University of Michigan 2008 Doctoral Committee: Professor James H. Woods, Chair Professor Margaret E. Gnegy Professor Shaomeng Wang Assistant Professor Roger K. Sunahara © Gregory T. Collins 2008 DEDICATION This thesis is dedicated to my parents, Thomas and Shirley Collins, without whom none of this would have been possible. Your continual support and encouragement throughout all of my endeavors has meant more than you will ever know. Thank you. ii ACKNOWLEDGMENTS First and foremost, I would like to thank my mentor, James Woods. You have been an exceptional mentor to me; I have learned more than I could have ever hoped. It has been a pleasure to work with someone who is so passionate and knowledgable, someone who has not only continued to challenge me, but has also provided an outstanding environment in which to study behavioral pharmacolgy. I truly feel lucky to have been able to learn from you. Of course, I also have to thank Gail Winger who has been a second mentor to me throughout the years. The support, encouragement, guidance, and patience that the two of you have provided has made for an exceptional experience. Thank you. I would also like to thank my committee, James Woods, Roger Sunahara, Peggy Gnegy and Shaomeng Wang. I am grateful to have been able to work with and learn from all of you over the years.
    [Show full text]
  • OTHER REVIEW(S) FOOD and DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion ****Pre-Decisional Agency Information****
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211150Orig1s000 OTHER REVIEW(S) FOOD AND DRUG ADMINISTRATION Center for Drug Evaluation and Research Office of Prescription Drug Promotion ****Pre-decisional Agency Information**** Memorandum Date: July 12, 2019 To: Brendan Muoio, Regulatory Project Manager Division of Psychiatry Products (DPP) Kimberly Updegraff, Associate Director for Labeling, DPP From: Dhara Shah, Regulatory Review Officer Office of Prescription Drug Promotion (OPDP) CC: Aline Moukhtara, Team Leader, OPDP Subject: OPDP Labeling Comments for WAKIX® (pitolisant) tablets, for oral use NDA: 211150 O-1 & O-2 In response to DPP’s consult request dated January 14, 2019, OPDP has reviewed the proposed product labeling (PI) and carton and container labeling for the original NDA submission for Wakix. PI: OPDP’s comments on the proposed labeling are based on the draft PI received by electronic mail from DPP (Brendan Muoio) on July 5, 2019, and are provided below. Carton and Container Labeling: OPDP has reviewed the attached proposed carton and container labeling submitted by the Sponsor and received by electronic mail from DPP (Brendan Muoio) on July 8, 2019, and we do not have any comments. Thank you for your consult. If you have any questions, please contact Dhara Shah at (240) 402-2859 or [email protected]. 26 Page(s) of Draft Labeling have been Withheld in Full as B4 (CCI/TS) immediately following this page 1 Reference ID: 4461481 Signature Page 1 of 1 -------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.
    [Show full text]
  • New Information of Dopaminergic Agents Based on Quantum Chemistry Calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A
    www.nature.com/scientificreports OPEN New information of dopaminergic agents based on quantum chemistry calculations Guillermo Goode‑Romero1*, Ulrika Winnberg2, Laura Domínguez1, Ilich A. Ibarra3, Rubicelia Vargas4, Elisabeth Winnberg5 & Ana Martínez6* Dopamine is an important neurotransmitter that plays a key role in a wide range of both locomotive and cognitive functions in humans. Disturbances on the dopaminergic system cause, among others, psychosis, Parkinson’s disease and Huntington’s disease. Antipsychotics are drugs that interact primarily with the dopamine receptors and are thus important for the control of psychosis and related disorders. These drugs function as agonists or antagonists and are classifed as such in the literature. However, there is still much to learn about the underlying mechanism of action of these drugs. The goal of this investigation is to analyze the intrinsic chemical reactivity, more specifcally, the electron donor–acceptor capacity of 217 molecules used as dopaminergic substances, particularly focusing on drugs used to treat psychosis. We analyzed 86 molecules categorized as agonists and 131 molecules classifed as antagonists, applying Density Functional Theory calculations. Results show that most of the agonists are electron donors, as is dopamine, whereas most of the antagonists are electron acceptors. Therefore, a new characterization based on the electron transfer capacity is proposed in this study. This new classifcation can guide the clinical decision‑making process based on the physiopathological knowledge of the dopaminergic diseases. During the second half of the last century, a movement referred to as the third revolution in psychiatry emerged, directly related to the development of new antipsychotic drugs for the treatment of psychosis.
    [Show full text]